自拟消导汤联合异维A酸红霉素凝胶治疗轻、中度寻常痤疮60例

目的观察自拟消导汤联合异维A酸红霉素凝胶治疗轻、中度寻常痤疮临床疗效。方法将180例患者随机分成三组,中药组60例,口服中药汤剂自拟消导汤;西药组60例,异维A酸红霉素凝胶晚上外用;联合组60例,口服中药汤剂自拟消导汤,同时夜间外用异维A酸红霉素凝胶。用药6周后观察疗效。结果三组有效率比较,差异有统计学意义（P〈0．05）。结论自拟消导汤联合异维A酸红霉素凝胶治疗轻、中度寻常痤疮临床疗效满意。     

新癀片联合异维A酸红霉素凝胶治疗寻常痤疮临床观察

目的观察新癀片联合异维A酸红霉素凝胶治疗寻常痤疮的临床疗效和安全性。方法将152例轻、中度寻常痤疮患者随机分为试验组(80例)和对照组(72例)。两组患者晚上睡觉前均外用异维A酸红霉素凝胶1次;试验组加用新癀片口服,每日3次,每次3片;疗程共6周。治疗2、4、6周随访,观察其临床疗效和不良反应。结果治疗2周后,试验组和对照组有效率分别为21.51%和14.29%,差异无统计学意义(P0.05);治疗4、6周后,试验组有效率(54.43%,84.81%)均显著高于对照组(30.00%,54.29%),差异均有统计学意义(P0.01)。药物相关不良反应主要为局部刺激症状,两组发生率分别为29.11%、29.58%,差异无统计学意义(P0.05)。结论新癀片联合异维A酸红霉素凝胶治疗寻常痤疮疗效满意、安全。     

丹参酮胶囊联合异维A酸红霉素凝胶治疗轻、中度寻常型痤疮疗效观察

目的探讨丹参酮胶囊联合异维A酸红霉素凝胶治疗轻、中度寻常型痤疮的疗效。方法将患者随机分为2组,治疗组46例,予丹参酮胶囊口服,4粒/次,3次/d,外用异维A酸红霉素凝胶,每晚1次;对照组44例,予异维A酸红霉素凝胶外用,每晚1次。疗程均为8周,2周复诊1次,观察记录疗效指标及不良反应。结果经8周治疗后,治疗组与对照组有效率分别为84.78%和59.09%,2组有效率相比差异有统计学意义(P0.05)。结论丹参酮胶囊和异维A酸红霉素凝胶联合使用是治疗轻、中度寻常痤疮的安全、有效的治疗办法。     

异维A酸红霉素凝胶联合多磺酸粘多糖乳膏治疗轻、中度寻常型痤疮临床观察

目的观察异维A酸红霉素凝胶联合多磺酸粘多糖乳膏治疗轻、中度寻常型痤疮的临床疗效。方法采用随机方法将156例轻、中度寻常型痤疮患者分为2组,治疗组应用异维A酸红霉素凝胶联合多磺酸粘多糖乳膏,对照组仅给予异维A酸红霉素凝胶,疗程6周,观察2组患者的疗效及留有瘢痕情况。结果治疗结束后治疗组与对照组的有效率分别为85.90%和67.95%,两组有效率的比较差异有统计学意义(χ~2=7.078,P 0.01),治疗组共2例患者留有瘢痕,对照组有9例,两组患者留有瘢痕的比较差异有统计学意义(χ~2=4.792,P 0.05)。结论异维A酸红霉素凝胶联合多磺酸粘多糖乳膏治疗轻、中度寻常型痤疮疗效可靠,且可降低瘢痕的形成,值得临床推广。     

异维A酸联合omega-3脂肪酸辅助治疗中重度寻常痤疮的临床疗效及不良反应评价

目的 评价异维A酸联合omega-3脂肪酸辅助治疗中重度寻常痤疮的临床疗效及不良反应.方法 招募中重度寻常痤疮患者,随机分为试验组和对照组.试验组口服omega-3脂肪酸+异维A酸,对照组口服异维A酸;外用药两组均为阿达帕林凝胶和过氧苯甲酰凝胶,治疗6个月后随访.检测并比较两组患者治疗前后面部痤疮综合分级系统(GAGS...     

异维A酸红霉素凝胶联合415nm蓝光治疗轻中度寻常痤疮疗效观察

[摘要] 目的：观察异维A酸红霉素凝胶联合蓝色LED光源治疗轻中度炎性痤疮的疗效。方法：将入选的120例患者随机分为三组,每组40例：一组用417nm蓝色LED光源治疗;一组用异维A酸红霉素凝胶治疗;一组用异维A酸红霉素凝胶联合蓝色LED光源治疗。使用数码相机分别记录治疗前及治疗后2、4、6周丘疹和脓疱的数目变化、观察治疗起效时间、疗效及不良反应。结果：异维A酸红霉素凝胶联合蓝色LED光源可以明显降低痤疮的炎性损害,起效时间较快,治疗结束后炎性损害仍可继续减少。结论：应用异维A酸红霉素凝胶联合417nm蓝色LED光源是治疗轻中度炎性痤疮的良好方法。     

中药配方颗粒剂配合维胺脂胶囊辨证分型治疗寻常痤疮60例疗效观察

目的观察中药配方颗粒剂配合维胺脂胶囊辨证分型治疗寻常痤疮的临床疗效。方法将入选的120例寻常痤疮患者随机分成两组。治疗组60例,口服痤疮中药配方颗粒剂,并于饭后口服维胺脂胶囊50mg,均3次/d,同时外用异维A酸红霉素凝胶,每晚1次;对照组60例,仅予口服维胺脂胶囊和外用异维A酸红霉素凝胶,用法同治疗组。两组患者的疗程均为4周。结果治疗组有效率95.00%,对照组有效率63.33%,差异有统计学意义(P0.01)。两组外用异维A酸红霉素凝胶后诉面部有不同程度的干燥、刺痛、鳞屑、潮红等不适,未见有胃肠道不良事件。结论中药配方颗粒配合维胺脂胶囊治疗寻常痤疮有效率高,服药方便,安全性好。     

异维A酸红霉素凝胶和维胺酯维E乳膏治疗寻常痤疮的随机平行对照研究

临床上各种外用维A酸制剂是治疗轻、中度寻常痤疮首选的方法之一,也是痤疮维持治疗的主要药物.此外,外用过氧化苯甲酰制剂和外用抗生素制剂也是治疗寻常痤疮的重要方法,其中外用红霉素是较常用的方法[1].有报道外用异维A酸制剂和红霉素联合使用有协同作用[2],而外用异维A酸的不良反应比外用全反式维A酸低[3].本试验使用异维A酸红霉素凝胶治疗寻常痤疮,观察其疗效和不良反应,并和维胺酯维E乳膏比较.     

火针联合阿达帕林凝胶治疗轻中度痤疮疗效评价

目的评价火针联合阿达帕林凝胶治疗轻、中度痤疮的有效性和安全性。方法选取门诊就诊的89例轻、中度痤疮患者,随机分为2组,试验组45例,对照组44例。试验组给予火针治疗,每周1次;外用阿达帕林凝胶治疗,每晚1次,治疗4周;对照组给予外用阿达帕林凝胶,每晚1次,治疗4周,比较两组患者临床疗效。结果治疗4周后试验组总有效率为95.56%,高于对照组,差异有统计学意义(P0.05)。结论火针联合阿达帕林凝胶治疗轻、中度痤疮有明显的疗效。     

异维A酸凝胶联合过氧苯甲酰凝胶治疗寻常痤疮疗效观察

目的：评价0.05%异维A酸凝胶联合5%过氧苯甲酰凝胶治疗轻中度寻常痤疮的疗效和安全性。方法：选择轻中度寻常痤疮患者为研究对象,采用随机、平行对照的试验方法。试验组患者早上外用5%过氧苯甲酰凝胶1次,晚睡前外用0.05%异维A酸凝胶1次;对照组患者仅晚睡前外用0.05%异维A酸凝胶1次。两组患者均用药8周。于用药后2、4和8周观察疗效和不良反应。结果：治疗2周后,试验组和对照组的有效率分别为17.8%和9.3%,差异无统计学意义（P〉0.05）;治疗4周后,试验组的有效率（55.6%）则显著高于对照组（32.6%）（P〈0.05）;治疗8周后试验组的有效率达到80.0%,显著高于对照组（58.1%）（P〈0.05）。药物相关不良反应主要为局部刺激反应,组间比较无统计学意义,两组患者用药过程中均未出现严重的全身不良反应。结论：0.05%异维A酸凝胶联合5%过氧苯甲酰凝胶治疗轻中度寻常痤疮较0.05%异维A酸凝胶单用起效快、疗效显著,是一种安全有效的治疗方法。     

异维A酸红霉素凝胶治疗轻、中度寻常性痤疮临床观察

目的观察异维A酸红霉素凝胶治疗轻、中度寻常性痤疮的疗效和安全性。方法采用单盲随机阳性药物对照的临床试验。治疗组采用异维A酸红霉素凝胶,每晚外用1次;对照组采用他扎罗汀乳膏,每晚外用1次,连续应用56天。结果治疗后,两组皮损数目均减少。治疗组和对照组有效率分别为80.56%和65.71%,差异有统计学意义(P<0.05);两组不良反应发生率分别为13.89%和21.34%,差异无统计学意义(P>0.05)。结论异维A酸红霉素凝胶治疗轻、中度寻常性痤疮安全有效,值得临床推广应用。     

Topical adapalene gel 0.1% vs. isotretinoin gel 0.05% in the treatment of acne vulgaris: a randomized open-label clinical trial

BACKGROUND: Topical application of isotretinoin and adapalene has proved effective in treating acne vulgaris. Both drugs demonstrate therapeutic advantages and less irritancy over tretinoin, the most widely used treatment for acne. They both act as retinoid agonists, but differ in their affinity profile for nuclear and cytosolic retinoic acid receptors. OBJECTIVE: To compare the efficacy and tolerability of adapalene gel 0.1% and isotretinoin gel 0.05% in the treatment of acne vulgaris of the face, in a randomized open-label clinical trial. METHODS: Eighty patients were enrolled and were instructed to apply adapalene gel 0.1% or isotretinoin gel 0.05% once daily over a 12-week treatment period. Efficacy determination included noninflammatory and inflammatory lesion counts by the investigator and global evaluation of improvement. Cutaneous tolerance was assessed by determining erythema, scaling and burning with pruritus. RESULTS: Adapalene and isotretinoin gels were highly effective in treating facial acne. Adapalene gel produced greater reductions in noninflammatory and inflammatory lesion counts than did isotretinoin gel, but differences between treatments were not statistically significant. Adapalene gel was significantly better tolerated than isotretinoin gel during the whole treatment period. CONCLUSIONS: The two gels studied demonstrated comparable efficacy. When adapalene and isotretinoin were compared, significantly lower skin irritation was noted with adapalene, indicating that adapalene may begin a new era of treatment with low-irritant retinoids.     

0.1%阿达帕林凝胶预防和减轻寻常痤疮复发的多中心随机对照临床试验

目的评价0.1%阿达帕林凝胶维持治疗对于预防和减轻寻常痤疮复发的作用.方法采用多中心、区组随机、开放、对照的方法,共入选患者246例,均为经过阿达帕林和克林霉素(特丽仙)联合治疗或特丽仙单独治疗获得有效(改善≥25%)的寻常痤疮患者,随机分为两组,一组外用0.1%阿达帕林凝胶,另一组不用药,均观察12周.结果239例患者完成治疗和观察,阿达帕林组121例,对照组118例.治疗4周后阿达帕林组炎性皮损数的减少显著优于对照组(P＜0.05),并维持至12周;治疗8周后阿达帕林组皮损总数和非炎性皮损数的减少也显著优于对照组(P＜0.01),并维持至12周.治疗结束后,阿达帕林组总体改善率为66.9%,对照组为4.2%(P＜0.01);阿达帕林组总复发率为4.1%,对照组为83.9%;两组间差异有显著性(P＜0.01).阿达帕林组有个别病例有轻度局部刺激反应,两组间不良反应差异无显著性(P＜0.05).结论阿达帕林凝胶可有效地治疗寻常痤疮,并维持治疗效果,且不增加局部刺激反应,对于减少病情复发具有显著效果.     

夫西地酸乳膏联合阿达帕林凝胶治疗寻常痤疮的临床观察

目的评价2%夫西地酸软膏联合0.1%阿达帕林凝胶治疗轻、中度寻常痤疮的临床疗效及安全性。方法寻常痤疮246例,随机分为3组,治疗组98例,采用2%夫西地酸软膏联合0.1%阿达帕林凝胶治疗;对照A组81例,采用1%克林霉素磷酸酯凝胶联合0.1%阿达帕林治疗;对照B组67例,单独使用0.1%阿达帕林凝胶治疗。均连用8周,分别在治疗后第2,4,8周末观察疗效并评价安全性。结果在治疗后第8周,治疗组有效率93.88%,与对照A组(81.48%)相比差异有统计学意义(P=0.010);治疗组Ⅲ级痤疮的有效率93.02%,与对照A组(69.70%)相比差异有统计学意义(P=0.007);疗程结束后,治疗组复发5例,复发率5.10%,远低于2个对照组。单独外用阿达帕林疗效均欠佳,且复发率较高。在治疗过程中,3组均未见明显不良反应。结论 2%夫西地酸软膏联合0.1%阿达帕林凝胶治疗轻、中度寻常痤疮具有疗效较好、复发率低、不良反应少等优点,是较理想的治疗方案。     

Adapalene 0.1%/Benzoyl Peroxide 2.5% Gel

Adapalene 0.1%/benzoyl peroxide 2.5% gel (Epiduo?, Tactuo?) is the only fixed-dose combination product available that combines a topical retinoid with benzoyl peroxide; it targets three of the four main pathophysiologic factors in acne. This article reviews the therapeutic efficacy and tolerability of topical adapalene 0.1%/benzoyl peroxide 2.5% gel in the treatment of patients aged ≥ 12 years with acne vulgaris, as well as summarizing its pharmacologic properties. In three 12-week trials in patients aged ≥12 years with moderate acne, success rates were significantly higher with adapalene 0.1%/benzoyl peroxide 2.5% gel than with adapalene 0.1% gel or benzoyl peroxide 2.5% gel alone, and combination therapy had an earlier onset of action. In addition, significantly greater reductions in total, inflammatory, and noninflammatory lesion counts were seen in patients receiving adapalene 0.1%/benzoyl peroxide 2.5% gel than in those receiving adapalene 0.1% gel or benzoyl peroxide 2.5% gel alone. Adapalene 0.1%/benzoyl peroxide 2.5% gel did not significantly differ from clindamycin 1%/benzoyl peroxide 5% gel in terms of the reduction in the inflammatory, noninflammatory, or total lesion counts in patients with mild to moderate acne, according to the results of a 12-week trial. Twelve-week studies showed that topical adapalene 0.1%/benzoyl peroxide 2.5% gel in combination with oral lymecycline was more effective than oral lymecycline alone in patients with moderate to severe acne, and topical adapalene 0.1%/benzoyl peroxide 2.5% gel in combination with oral doxycycline hyclate was more effective than oral doxycycline hyclate alone in patients with severe acne. In patients with severe acne who responded to 12 weeks’ therapy with topical adapalene 0.1%/benzoyl peroxide 2.5% gel plus oral doxycycline hyclate or oral doxycycline hyclate alone, an additional 6 months’ therapy with adapalene 0.1%/benzoyl peroxide 2.5% gel was more effective than vehicle gel at maintaining response, with further improvement seen in adapalene 0.1%/benzoyl peroxide 2.5% gel recipients. A noncomparative study also demonstrated the efficacy of 12 months’ therapy with adapalene 0.1%/benzoyl peroxide 2.5% gel in patients with acne vulgaris. Topical adapalene 0.1%/benzoyl peroxide 2.5% gel was generally well tolerated in patients with acne. In 12-week trials, the most commonly occurring treatment-related adverse events included erythema, scaling, dryness, and stinging/burning; these dermatologic treatment-related adverse events were usually of mild to moderate severity, occurred early in the course of treatment, and resolved without residual effects. Topical adapalene 0.1%/benzoyl peroxide 2.5% gel was generally well tolerated in the longer term, with dry skin being the most commonly occurring treatment-related adverse event over 12 months of treatment. In conclusion, adapalene 0.1%/benzoyl peroxide 2.5% gel is a valuable agent for the first-line treatment of acne vulgaris.     

维胺酯和异维A酸治疗寻常痤疮随机双盲研究

目的 评价维胺酯胶囊和异维A酸胶丸治疗中重度寻常痤疮的疗效和安全性.方法 采用多中心、随机、双肓双模拟、对照临床研究,按痤疮综合分析系统(GAGS)评价痤疮的严重程度,将评分确定为中重度痤疮的患者随机分为维胺酯组(50mg,每日3次)和异维A酸组(10mg,每日2次),于服药前、服药后2、4、6周计数皮损,观察疗效和不良反应.结果 共入组227例,计入全分析集(FAS)分析213例,符合方案集(PPS)分析200例.PPS分析治疗后2、4、6周异维A酸组有效率分别为6.0%、29.0%、57.0%;维胺酯组分别为5.0%、20.0%、51.00%,两组比较差异无统计学意义(P>0.05).各随访期皮损数下降值比较,除异维A酸组炎性丘疹和脓疱数下降值高于维胺酯组(P<0.05)外,粉刺、结节类皮损数两组差异无统计学意义.FAS分析不良反应发生率异维A酸组(68.81%)显著高于维胺酯组(36.53%)(P<0.001),常见不良反应如口干、口唇脱屑异维A酸组发生率显著高于维胺酯组(P<0.001),不良反应的程度也明显重于维胺酯组(P<0.05).结论 异维A酸和维胺酯治疗中重度痤疮疗效较为一致,但异维A酸治疗炎性皮疹起效较快,同时其常见不良反应也多于维胺酯.     

Clinical and microbiological comparisons of isotretinoin vs. tetracycline in acne vulgaris

The aim of this study was to compare the clinical and microbiological effect on Propionibacterium acnes of oral tetracycline plus topical adapalene vs. oral isotretinoin in moderate to severe acne vulgaris. Male and female acne patients with moderate or severe inflammatory disease were enrolled and assigned randomly to 6 months of treatment with oral tetracycline hydrochloride plus topical adapalene, or oral isotretinoin, in a controlled, open study. After cessation of oral treatment the antibiotic-treated group received topical adapalene for the 2-month follow-up period. Clinical and microbiological assessments were performed. Skin samples for microbial identification and quantification were taken at baseline, after 2, 4 and 6 months of treatment, and 2 months after cessation of treatment. Patients treated with isotretinoin showed prolonged significant remission compared with the other group. The density of resistant propionibacteria did not change significantly in any of the groups and there was no correlation between resistant P. acnes and the clinical response in any of the regions investigated. Antibiotic treatment was found to be a good alternative to isotretinoin, regardless of the presence of antibiotic-resistant P. acnes, although isotretinoin had a better effect, with prolonged remission after treatment.     

0.1%阿达帕林凝胶和1%克林霉素溶液联合外用治疗寻常痤疮临床观察

目的:比较0.1%阿达帕林凝胶(达芙文)与1%克林霉素磷酸酯溶液(特丽仙)联合外用与特丽仙单用治疗寻常痤疮的疗效和安全性。方法:将300例中至重度寻常痤疮患者分为两组,试验组联合外用达芙文和特丽仙,对照组单用特丽仙,两组共治疗12周。结果:274例患者完成治疗,治疗4周后试验组皮损总数改善显著优于对照组(P<0.05),并维持至12周;治疗8周后试验组炎性皮损和非炎性皮损改善优于对照组(P<0.01),并维持至12周。治疗结束后试验组和对照组的有效率分别为84.40%和72.93%(P<0.05)。试验组局部刺激反应发生率为4.0%,对照组为8.7%。结论:达芙文联合特丽仙治疗中至重度寻常痤疮的疗效比单用特丽仙的效果好。